BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21495998)

  • 1. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
    Liang CP; Yang CS; Shen JL; Chen YJ
    Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-induced acute pancreatitis.
    Saadati H; Saif MW
    JOP; 2010 May; 11(3):283-4. PubMed ID: 20442531
    [No Abstract]   [Full Text] [Related]  

  • 3. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
    Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib-induced bilateral osteonecrosis of femoral heads.
    Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
    J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
    [No Abstract]   [Full Text] [Related]  

  • 9. Localized dyskeratotic plaque with milia associated with sorafenib.
    Chappell JA; Burkemper NM; Semchyshyn N
    J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
    Mancuso A; Airoldi A; Vigano R; Pinzello G
    Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment.
    Tougeron D; Wierzbicka-Hainaut E; Osdoit S; Chagneau-Derrode C; Yacoub M; Silvain C
    Eur J Dermatol; 2010; 20(6):854-6. PubMed ID: 20956109
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
    Lucas E; Aubourg A; Bacq Y; Perarnau JM
    Dig Liver Dis; 2011 Nov; 43(11):920. PubMed ID: 21763223
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
    Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR; Stetson CL; Smith JL
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML; Chon SY
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythema multiforme induced by sorafenib.
    Feltes RA; Feito Rodríguez M; González-Beato MJ
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.